ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

LOXO-305, an oral BTK inhibitor, is designed to address acquired resistance to currently available BTK inhibitors, such as J&J’s Imbruvica.

Roche pays $775m upfront to access Blueprint’s RET programme

to currently available BTK inhibitors, such as Johnson &Johnson’s Imbruvica (ibrutinib).

EU grants approval for Venclyxto/Gazyvaro combo in CLL

It also has to contend with the combination of AbbVie’s Imbruvica (ibrutinib) plus Gazyvaro, which became the first chemo-free option for first-line CLL therapy last year.

AZ revenues rise, but it says coronavirus could hit 2020

Recently-approved for a new chronic lymphocytic leukaemia (CLL) indication, AZ’s rival to Johnson &Johnson’s blockbuster BTK inhibitor Imbruvica (ibrutinib) – Calquence (acalabrutinib) – also gathered momentum and contributed $56m in

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]